As an adjunct to diet due to inadequate response to diet restricted in saturated fat & cholesterol, & other nonpharmacologic measures alone; can be started simultaneously w/ diet in patients w/ CHD or CHD-multiple risk factors. CV disease prevention: Reduces risk of MI, stroke, revascularization procedures & angina in adults w/o clinically evident CHD, but w/ CHD-multiple risk factors (eg, age, smoking, HTN, low HDL-C or a family history of early CHD); reduces risk of MI & stroke in patients w/ type 2 diabetes & w/o clinically evident CHD but w/ multiple CHD risk factors (eg, retinopathy, albuminuria, smoking, or HTN). Reduces risk of non-fatal MI, fatal & non-fatal stroke, for revascularization procedures, hospitalization for CHF, & angina in patients w/ clinically evident CHD. Hyperlipidemia: Primary hypercholesterolemia (heterozygous familial & nonfamilial) & mixed dyslipidemia (Fredrickson type IIa & IIb) as an adjunct to diet; patients w/ elevated serum triglyceride levels (Fredrickson type IV) as an adjunct to diet; primary dysbetalipoproteinemia (Fredrickson type III) in patients w/o adequate response to diet; total cholesterol & LDL-cholesterol (LDL-C) reduction in homozygous familial hypercholesterolemia as adjunct to other lipid-lowering treatments (eg, LDL apheresis); total cholesterol, LDL-C & apolipoprotein B level reduction for heterozygous familial hypercholesterolemia in boys & postmenarchal girls 10-17 yr as an adjunct to diet, if an adequate trial of diet therapy the following findings are present: LDL C remains ≥190 mg/dL, or LDL-C remains ≥160 mg/dL & w/ positive family history of premature CV disease or ≥2 other CV disease risk factors present in ped patients.